China Nuokang Bio-Pharmaceutical Inc.  

(Public, NASDAQ:NKBP)   Watch this stock  
Find more results for NASDAQ: NKBP
Feb 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 108.95M
P/E     -
Div/yield     -
EPS -0.28
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin 3.34% -4.90%
Operating margin 6.76% 6.47%
EBITD margin - 20.60%
Return on average assets 1.41% -1.95%
Return on average equity 1.62% -2.24%
Employees 454 -
CDP Score - -


No. 18-1 East Nanping Road Hunnan Natnl New & High-tch Dvlpmnt Zone
+86-24-24696033 (Phone)
+86-24-24696133 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on research, development, manufacture, marketing and sales of hospital-based medical products. As of December 31, 2010, it sold a portfolio of 15 products, including four principal products: Baquting, its bleeding control product; Kaitong, its lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; Aiduo, its cardiovascular stress imaging agent, and Aiwen, its anti-arrhythmic agent. Its product pipeline includes three product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. In February 2013, it announced the completion of the merger with Kingbird Mergerco. Inc., a wholly owned subsidiary of Kingbird Investment Inc. As a result of the merger the Company became a wholly owned subsidiary of Kingbird Investment Inc.